Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9996713 | 0.86 | — | — | |
| SCHEMBL3955899 | 0.81 | SMN1; SMN2 (0.45) | SMN1; SMN2HRH3EPHX1EPHX2HSD11B1 | |
| SCHEMBL771690 | 0.81 | DRD2 (0.44) | EPHX1EPHX2 | |
| SCHEMBL22793920 | 0.79 | SMN1; SMN2 (0.46) | SMN1; SMN2HRH3EPHX1EPHX2HSD11B1 | |
| SCHEMBL178287 | 0.79 | SMN1; SMN2 (0.46) | SMN1; SMN2HRH3EPHX1EPHX2HSD11B1 | |
| SCHEMBL31273888 | 0.79 | HRH3 (0.49) | SMN1; SMN2HRH3EPHX1EPHX2HSD11B1 | |
| SCHEMBL8988954 | 0.78 | HRH3 (0.41) | SMN1; SMN2HRH3EPHX1EPHX2HSD11B1 | |
| SCHEMBL22520700 | 0.75 | ACHE (0.50) | SMN1; SMN2HRH3HSD11B1KDM4E | |
| SCHEMBL102378 | 0.75 | NCF1 (0.58) | SMN1; SMN2HRH3EPHX1EPHX2HSD11B1 | |
| SCHEMBL21532979 | 0.75 | SMN1; SMN2 (0.43) | SMN1; SMN2HRH3EPHX1EPHX2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106061990-A | Abiraterone derivative, and preparation method therefor and medical applications thereof | 四川海思科制药有限公司 | 2016-10-26 | — | — | CN | disclosed |
| US-8895565-B2 | Heterocyclic compound and use of the same | NISHIO TETSUYA (JP) | 2014-11-25 | — | — | US | disclosed |
| WO-2014179496-A1 | SERINE/THREONINE KINASE INHIBITORS | AFRAXIS HOLDINGS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179498-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| US-20140323477-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140323478-A1 | SERINE/THREONINE KINASE INHIBITORS | AFRAXIS HOLDINGS, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-8492560-B2 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2013-07-23 | — | — | US | disclosed |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | STOKES ELAINE S E (GB) | 2012-08-02 | — | — | US | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20110319618-A1 | HETEROCYCLIC COMPOUND AND USE OF THE SAME | NISHIO TETSUYA (JP) | 2011-12-29 | — | — | US | disclosed |
| EP-0450066-B1 | CARBOSTYRIL DERIVATIVES | OTSUKA PHARMA CO LTD (JP) | 1996-09-11 | — | — | EP | disclosed |
| US-5488140-A | ANTICONVULSANTS | CIBA-GEIGY CORPORATION (US) | 1996-01-30 | — | — | US | disclosed |
| EP-0420806-B1 | Phosphonic acids, process for preparation and use as an active pharmaceutical composition | CIBA GEIGY AG (CH) | 1995-07-05 | — | — | EP | disclosed |
| US-5401740-A | FOR INHIBITING PLATELET AGGREGATION | OTSUKA PHARMACEUTICAL CO. (JP) | 1995-03-28 | — | — | US | disclosed |
| US-5294734-A | 1-phosphato-4-amino-pent-2-enoic acids and derivatives | CIBA-GEIGY CORP. (US) | 1994-03-15 | — | — | US | disclosed |
| US-5227381-A | Anticoagulant | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-07-13 | — | — | US | disclosed |
| EP-0450066-A1 | CARBOSTYRIL DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-10-09 | — | — | EP | disclosed |
| EP-0420806-A1 | Phosphonic acids, process for preparation and use as an active pharmaceutical composition | CIBA-GEIGY AG (CH) | 1991-04-03 | — | — | EP | disclosed |
| US-4440781-A | TRANQUILIZERS; ANTICONVULSANTS; ANTIDEPRESSANTS; ALCOHOL AND TOBACCO WITHDRAWAL | THE VINOXEN COMPANY, INC. (US) | 1984-04-03 | — | — | US | disclosed |
| US-4424202-A | Azelaaldehydates as psychotropic agents | THE VINOXEN COMPANY, INC. (US) | 1984-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323478-A1 | SERINE/THREONINE KINASE INHIBITORS | PAK1, PAK2, AKT1 | SMN1; SMN2 1834/4885HRH3 2420/4885EPHX1 2538/4885 |
| US-20110319618-A1 | HETEROCYCLIC COMPOUND AND USE OF THE SAME | CYP2D6, CYP2B6, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | SMN1; SMN2 4130/4885HRH3 92/4885EPHX1 1730/4885 |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | VEGFA, FLT1, KDR | SMN1; SMN2 4479/4885HRH3 739/4885EPHX1 3354/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | SMN1; SMN2 4306/4885HRH3 4130/4885EPHX1 3653/4885 |
| US-20140323477-A1 | SERINE/THREONINE KINASE INHIBITORS | PAK1, PAK2, AKT1 | SMN1; SMN2 1711/4885HRH3 2388/4885EPHX1 2465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.